1. Home
  2. CINGW vs BDTX Comparison

CINGW vs BDTX Comparison

Compare CINGW & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • BDTX
  • Stock Information
  • Founded
  • CINGW N/A
  • BDTX 2014
  • Country
  • CINGW United States
  • BDTX United States
  • Employees
  • CINGW 13
  • BDTX N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • BDTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CINGW Health Care
  • BDTX Health Care
  • Exchange
  • CINGW Nasdaq
  • BDTX Nasdaq
  • Market Cap
  • CINGW N/A
  • BDTX N/A
  • IPO Year
  • CINGW 2021
  • BDTX 2020
  • Fundamental
  • Price
  • CINGW $0.03
  • BDTX $1.64
  • Analyst Decision
  • CINGW
  • BDTX Strong Buy
  • Analyst Count
  • CINGW 0
  • BDTX 5
  • Target Price
  • CINGW N/A
  • BDTX $15.60
  • AVG Volume (30 Days)
  • CINGW N/A
  • BDTX 750.1K
  • Earning Date
  • CINGW N/A
  • BDTX 05-20-2025
  • Dividend Yield
  • CINGW N/A
  • BDTX N/A
  • EPS Growth
  • CINGW N/A
  • BDTX N/A
  • EPS
  • CINGW N/A
  • BDTX N/A
  • Revenue
  • CINGW N/A
  • BDTX N/A
  • Revenue This Year
  • CINGW N/A
  • BDTX N/A
  • Revenue Next Year
  • CINGW N/A
  • BDTX N/A
  • P/E Ratio
  • CINGW N/A
  • BDTX N/A
  • Revenue Growth
  • CINGW N/A
  • BDTX N/A
  • 52 Week Low
  • CINGW N/A
  • BDTX $1.20
  • 52 Week High
  • CINGW N/A
  • BDTX $7.38
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • BDTX 51.94
  • Support Level
  • CINGW N/A
  • BDTX $1.46
  • Resistance Level
  • CINGW N/A
  • BDTX $1.78
  • Average True Range (ATR)
  • CINGW 0.00
  • BDTX 0.11
  • MACD
  • CINGW 0.00
  • BDTX 0.02
  • Stochastic Oscillator
  • CINGW 0.00
  • BDTX 54.55

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: